Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Table 3 Univariate and multivariate cox proportional hazard model for Median progression-free survival

Characteristic	N	Univariate			Multivariate
		mPFS	95%CI	P value	HR	95%CI	P value
Treatment				0.000	0.25	0.12-0.52	< 0.001
PTL group	18	5.4	3.61-7.25
TL group	23	2.7	1.73-3.61
Gender				0.162	-	-	0.947
Male	33	4.00	2.70-5.31
Female	8	3.37	2.44-4.30
Age				0.902	-	-	0.740
≥ 55 yr	26	3.70	3.13-4.28
< 55 yr	15	3.63	1.96-5.30
Liver cirrhosis				0.015	-	-	-
Yes	40	3.7	3.39-4.01
No	1	1.17	-
Weight				0.537	-	-	-
< 60 kg	15	3.73	3.48-3.98
≥ 60 kg	26	3.27	1.87-4.67
Etiology				0.729	-	-	-
HBV	38	3.7	3.16-4.24
Others	3	4.47	0.36-8.58
PVTT				0.389	-	-	0.704
Ⅰ-Ⅱ types	15	3.7	0.76-6.64
Ⅲ-Ⅳ types	26	3.7	2.95-4.45
TACE				0.214	-	-	-
1-2 times	29	3.83	3.18-4.48
≥ 2 times	12	3.37	2.57-4.17
ECOG-PS				0.036	2.82	1.29-6.16	0.009
< 1	14	5.43	2.55-8.31
≥ 1	27	3.27	2.69-3.85
Child-Pugh grade				0.027	0.10	0.01-1.11	0.061
A	39	3.73	3.28-4.18
B	2	1.83	-
AFP				0.177	-	-	-
< 40 0 ng/mL	20	3.63	2.94-4.32
≥ 400 ng/mL	21	4.43	2.79-6.08
Extrahepatic spread				0.233	-	-	-
Yes	40	3.7	2.82-4.58
No	1	3.7	2.54-4.86
Tumor diameter				0.959	-	-	-
< 5 cm	5	4.43	1.94-6.92
≥ 5 cm	36	3.70	3.17-4.23
Anti-viral therapy				0.714	-	-	-
Yes	38	3.7	3.01-4.40
No	3	3.7	0.82-6.58
ALB				0.840	-	-	-
> 3.5 g/dL	17	3.37	2.21-4.53
≤ 3.5 g/dL	24	3.73	3.17-4.30
Family history of HBV				0.099	-	-	-
Yes	28	4.43	3.60-5.26
No	13	2.67	1.03-4.28
PT				0.561	-	-	0.915
< 13 s	25	4.00	2.69-5.31
≥ 13 s	16	2.53	0.04-5.02
TBIL				0.964	-	-	0.392
< 1.5 mg/dL	31	3.73	2.86-4.60
≥ 1.5 mg/dL	10	2.67	1.90-3.45
ALT				0.907	-	-	-
< 40 µg/mL	22	3.73	2.11-5.35
≥ 40 µg/mL	19	3.70	3.24-4.16
AST				0.849	-	-	-
< 40 µg/mL	12	3.23	1.43-5.03
≥ 40 µg/mL	29	3.70	3.12-4.28

PTL: PD-1 inhibitor/transcatheter arterial chemoembolization/Lenvatinib; TL: Transcatheter arterial chemoembolization/Lenvatinib; PVTT: Portal vein tumor thrombus; TACE: Transcatheter arterial chemoembolization; ECOG-PS: Eastern Cooperative Oncology Group-performance status; AFP: Alpha fetoprotein; ALB: Albumin; HBV: Hepatitis B virus; PT: Prothrombin time; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate transaminase.